Viral Vector News and Research

RSS

Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.

Study: A considerable number of healthcare workers took sick leave after COVID-19 vaccination

A third of healthcare workers took sick leave after being vaccinated against COVID-19, a German study presented at this year's European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal, (23-26 April) has found.

23 Apr 2022

Hybrid alphavirus-SARS-CoV-2 pseudovirus system rapidly measures neutralizing antibodies

Do a person's antibodies work to block the COVID-19 virus from infecting one's system? Are these antibodies also capable of blocking emerging variants such as the omicrons?

21 Apr 2022

Does COVID-19 vaccination benefit those with prior SARS-CoV-2 infection?

Researchers evaluate the effectiveness of four COVID-19 vaccines against symptomatic infection, hospitalization, and death in convalescent individuals.

5 Apr 2022

Preclinical investigation of intranasal adjuvanted COVID-19 vaccine

A new study reported systemic and mucosal immunity against SARS-CoV-2 via intranasal delivery of a vaccine containing recombinant SARS-CoV-2 antigens, nucleocapsid, and spike subunit.

30 Mar 2022

Study evaluates humoral and cellular immune memory induced by different COVID-19 vaccines

Researchers evaluated the humoral and cellular immune memory induced by four COVID-19 vaccines representing three different vaccine platforms.

24 Mar 2022

New approach could lead to quicker generation of effective, personalized cancer vaccines

Scientists have created a pipeline for identifying, prioritizing and evaluating potential tumor antigens for the fast generation of cancer vaccines, according to a report published today in eLife.

22 Mar 2022

Study shows BCG vaccination reduces SARS-CoV-2-induced lung inflammation in hamsters

Researchers tested the effectiveness of the BCG vaccine in SARS-CoV-2-infected Syrian hamsters.

18 Mar 2022

Synthetic viral vector and surgical approach enable efficient gene transfer into the inner ear of primates

A synthetic viral vector and a novel surgical approach developed at Mass Eye and Ear has enabled efficient gene transfer into the inner ear of nonhuman primates, a research team working towards the development of effective treatments for hearing loss and vestibular disorders has reported.

15 Mar 2022

Three new drug companies join the COVIDRIVE consortium to study vaccine effectiveness

Three new drug companies (Moderna, Novavax and Valneva) have joined the COVIDRIVE consortium, becoming partners of this project coordinated by the Vaccine Research Department of the Foundation for the Promotion of Health and Biomedical Research of Valencia Region (Fisabio), an affiliate of the Conselleria de Sanitat Universal i Salut Pública, along with the company specialized in pharmacovigilance and epidemiology, P95.

8 Mar 2022

Intersectional, anterograde transsynaptic targeting system used to reveal two different brain circuits

Osaka Metropolitan University uses new “intersectional, anterograde transsynaptic targeting system” to reveal two different mouse brain circuits: the retina/primary visual cortex to the superior colliculus and the bilateral motor cortex to the dorsal striatum.

8 Mar 2022

Current progress in SARS-CoV-2 vaccine candidates

In a new study, researchers illustrated the current progress and obstacles in COVID-19 vaccine development.

7 Mar 2022

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Researchers estimated the immunogenicity of SARS-CoV-2 vaccination in a Belgian cohort of patients with ankylosing spondylitis.

7 Mar 2022

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

A new study assesses breakthrough SARS-CoV-2 infections in vaccinated CLD patients with cirrhosis as compared to CLD patients without cirrhosis.

3 Mar 2022

Additional doses of covid-19 vaccine recommended for immunocompromised patients

Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, say experts in The BMJ today.

3 Mar 2022

Study compares heterologous and homologous third vaccination in kidney transplant recipients

A new study assesses the comparative neutralizing antibody level elicited by three mRNA vaccine doses to a heterologous COVID-19 vaccine regimen.

28 Feb 2022

Breakthrough SARS-CoV-2 infection peaks at 5 months

A new study describes the incidence of breakthrough infection with SARS-CoV-2 after vaccination with one of the nucleic acid or viral vector vaccines.

28 Feb 2022

Emergence of SARS-CoV-2 Omicron likely due to immune selective pressure

A new study discusses the emergence of new variants of SARS-CoV-2 that can escape antibody-mediated neutralization, as opposed to other Sarbecoviruses.

27 Feb 2022

A comparison of COVID-19 vaccines by neutralizing antibody potency

Researchers use an international standardized assessment method to compare the efficacy of antibody responses to the major COVID-19 vaccines.

24 Feb 2022

Gradual decline in pathogenicity and enhanced cytokine induction in SARS-CoV-2 variants

A new study focuses on understanding the factors associated with the ability of the Omicron variant to infect a wide range of age groups.

20 Feb 2022

TTUHSC project awarded new NIH grant to advance research on amygdala pain mechanisms

It is estimated that more than 100 million U.S. adults are affected by chronic pain, a condition that annually costs the country an estimated $560-635 billion in health care costs, disability and lost productivity.

1 Feb 2022